Recent business developments include strategic acquisition plans, regulatory progress for key product candidates, positive clinical data announcements, and exploration of new investment opportunities leveraging a strong financial position.

• Polyrizon signed a memorandum of understanding to acquire up to a 20% stake in Colugo, with the stock price declining in pre-market trading following the announcement [N1].
• The company plans to acquire a 51% stake in a global private aviation company, as announced in February 2026 [N3][N4].
• Polyrizon advanced the regulatory path for its NASARIX™ allergy blocker by initiating a usability study program aligned with FDA requirements [N5].
• The company is exploring revenue-generating investment opportunities in high-growth sectors, leveraging its strong cash position and debt-free balance sheet [N6].
• Positive data from the PL-14 allergy blocker formulation study was announced, supporting ongoing clinical development [N7].
• Polyrizon submitted a pre-request with the FDA for its PL-16 viral blocker product candidate, initiating formal regulatory discussions [N8].

Polyrizon's innovative hydrogel nasal spray technologies address significant unmet needs in allergy relief and viral protection, with product candidates advancing through regulatory pathways. The company's strong liquidity and debt-free balance sheet support ongoing clinical development and strategic acquisitions. Positive preclinical and clinical data, along with regulatory engagement with the FDA, demonstrate progress toward commercialization. The adaptable nature of its technology platforms allows potential rapid response to emerging medical challenges, and partnerships with scientific experts and manufacturers enhance development capabilities.

Polyrizon faces risks typical of development stage biotech companies, including regulatory uncertainties, clinical trial outcomes, and competitive pressures from larger pharmaceutical and medical device companies. The company's reliance on third-party manufacturers and suppliers introduces operational risks. Cybersecurity incidents have occurred, highlighting potential vulnerabilities. The regulatory pathways, while potentially streamlined, may still involve delays or require more rigorous review than anticipated. The company's financial results show net losses, and there is no disclosed revenue, indicating ongoing funding needs and execution risks.

Polyrizon's moat is based on its proprietary hydrogel technologies (C&C and T&T) that provide a physical barrier and targeted drug delivery via nasal sprays, leveraging renewable, biodegradable, and biocompatible polymers. The company's focus on FDA Class II medical device regulatory pathways for its product candidates may offer a relatively streamlined approval process compared to traditional pharmaceuticals. Its collaborations with scientific experts and third-party manufacturers, along with a patent license agreement for the SCI-160 platform, contribute to its technological and operational positioning. However, the company operates in a competitive landscape with larger, more established players possessing greater resources and experience in drug development and commercialization.

• Regulatory Risk: The FDA may require more extensive review or different regulatory pathways than anticipated, potentially delaying product approvals and commercialization.
• Clinical Development Risk: Product candidates are in early stages of development with ongoing preclinical and clinical studies; failure to demonstrate safety and efficacy could impede progress.
• Competitive Risk: The company faces competition from larger, more established pharmaceutical and medical device companies with greater resources and market presence.
• Operational Risk: Dependence on third-party manufacturers and suppliers for clinical trial materials and raw materials may affect timelines and quality control.
• Cybersecurity Risk: Past incidents of fraudulent wire transfers due to email compromise highlight vulnerabilities that could impact financial and operational integrity.

• Polyrizon Ltd. is a development stage biotech company incorporated in Israel in 2005, specializing in innovative medical device hydrogels delivered as nasal sprays that form a physical barrier in the nasal cavity against viruses and allergens, referred to as C&C technology, and a separate platform called T&T focused on nasal delivery of active pharmaceutical ingredients (APIs).
• The C&C hydrogel technology is composed of naturally occurring building blocks and mucoadhesive polymers such as sodium alginate, which are FDA GRAS (Generally Recognized As Safe). The technology acts as a 'biological mask' by creating a thin shield containment barrier in the nasal cavity without chemical action.
• Polyrizon's leading product candidates include PL-14 (branded NASARIX™), a nasal allergy blocker expected to be regulated as a Class II medical device via the FDA 510(k) pathway, and PL-16, an influenza blocker expected to be regulated as a Class II medical device via the De Novo Classification request pathway.
• NASARIX™ has completed branding, GMP batch production of clinical trial material, positive preclinical allergen-blocking performance, strong tolerability in human nasal tissue models, and initiation of a human factors/usability study aligned with FDA requirements.
• PL-16 submitted a Pre-Request for Designation (Pre-RFD) to the FDA in December 2025 to determine the regulatory pathway and initiated preclinical safety trials in Q2 2025. Clinical feasibility trials are planned for Q3 2027 and pivotal trials for Q3 2028.
• The T&T platform is designed for sustained release of APIs with targeted delivery, focusing on corticosteroids, benzodiazepines, and naloxone, with feasibility studies ongoing through Q3 2026 and preclinical studies planned to start thereafter.
• Polyrizon has entered into a patent license agreement with SciSparc Ltd. for the SCI-160 platform related to pain treatment, with milestone payments and royalties structured in the agreement.
• The company relies on third-party manufacturers and suppliers for raw materials and clinical trial supplies, including a master services agreement with Eurofins for GMP manufacturing of NASARIX™ clinical trial material.
• Polyrizon is an emerging growth company and a foreign private issuer under U.S. securities laws, benefiting from certain reduced reporting and disclosure requirements.
• Financial snapshot as of December 31, 2025: cash and equivalents of $1.306 million, current assets of $12.86 million, current liabilities of $0.443 million, net loss of $3.335 million, and basic and diluted EPS of $4.9 per share. The current ratio is 29.03 and cash ratio is 3.03, indicating strong liquidity.
• The company has no subsidiaries and operates primarily from offices and R&D facilities in Israel under month-to-month leases.
• Recent business developments include signing a memorandum of understanding to acquire up to 20% stake in Colugo, plans to acquire 51% stake in a global private aviation company, advancing regulatory pathways for NASARIX™ allergy blocker, and exploring revenue-generating investment opportunities leveraging a strong cash position and debt-free balance sheet.
• Polyrizon has reported positive data from PL-14 allergy blocker formulation studies and submitted a pre-request with FDA for PL-16 viral blocker.
• The company has secured continued Nasdaq listing following compliance plan implementation and has experienced cybersecurity incidents involving fraudulent wire transfers, which were promptly addressed with enhanced controls.
• Polyrizon's management team has extensive life sciences industry experience, supported by a scientific advisory board of experts in drug delivery and pharmaceuticals.
• The company faces competition from pharmaceutical and medical device companies developing nasal barrier products and intranasal drug delivery systems, with competitors having greater resources and experience.
• Polyrizon's C&C technology aims to address unmet needs in healthcare such as allergic rhinitis and viral infections, while the T&T platform targets markets including allergic/non-allergic rhinitis, opioid overdose treatment, and seizure cluster management.